18

Abstract

Objectives: Numerous operative procedures have been described for the reconstruction of acromioclavicular joint (ACJ) separation, however the arthroscopic reconstruction has been rarely reported. Our objective was to present a new, fully arthroscopic technique for the ACJ stabilization and to present first results after 2 years of follow-up. Methods: Up to now, thirty-two patients underwent arthroscopic ACJ reconstruction using suture anchors Corkscrew #5 (Arthrex Inc, Naples, FL) armed with FiberWire #5, which were tied over a small titanium plate inserted over a skin incision of about only 2 cm. Two anchors were inserted using a special delivery device under arthroscopic view in the base of the coracoid at the anatomic origin of the coracoclavicular ligaments. Indications for surgery included ACJ dislocation Rockwood type IV and V. The first thirteen patients have now a mean follow-up of 24 months (average age of 40.2 years; range, 23 to 54 years) and were evaluated using Constant score and radiographs. Results: 12/13 patients returned to their work without pain within 3 months after operation. The average Constant score at last follow-up was 95. Postoperative radiographs confirmed anatomic reduction in 10 patients, residual subluxation in 2 patients and redislocation of the joint in 1 patient. One patient had radiographic evidence of coracoclavicular ossification. All patients but one were satisfied with results and cosmetic appearance. Conclusion: Considering its less morbidity, excellent cosmetics, no need to remove an implant, and minimal complications from breakage or migration of metal implants, this new technique offers an attractive alternative in acromioclavicular joint stabilization. If noted, the author indicates something of value received. The codes are identified as follows: a, research or institutional support; b, miscellaneous funding; c, royalties; d, stock options; e, consultant or employee. *The Food and Drug Administration has not cleared the drug and/or medical device for the use described in this presentation (ie, the drug or medical device is being discussed for an “off-label” use). If noted, the author indicates something of value received. The codes are identified as follows: a, research or institutional support; b, miscellaneous funding; c, royalties; d, stock options; e, consultant or employee. *The Food and Drug Administration has not cleared the drug and/or medical device for the use described in this presentation (ie, the drug or medical device is being discussed for an “off-label” use).